Rasonque Gains CHMP Positive Opinion for Metastatic Pancreatic Cancer

A phased review timeline of under 150 active days, roughly 60 days shorter than the 210-day standard evaluation, is now on record as a viable pathway to CHMP positive opinion, following the committee's recommendation to authorise Rasonque (daraxonrasib) for adults with metastatic pancreatic adenocarcinoma who have received at least one prior line of therapy. For regulatory affairs leads benchmarking submission strategies for high-priority oncology candidates, the Rasonque dossier represents the first concrete data point under EMA's Cancer Medicines Pathfinder project.

The phased review, which opened in early July 2026, permitted CHMP to begin assessing quality, non-clinical, and clinical data packages as they were submitted, rather than awaiting a complete application. EMA has confirmed that lessons drawn from this evaluation will directly inform implementation of phased reviews under the EU's new pharmaceutical legislation, where the mechanism is positioned as a standing tool for agile assessment of medicines addressing unmet medical need.

Daraxonrasib is a RAS inhibitor that binds to cyclophilin A, forming a complex that blocks constitutively active RAS proteins, the product of RAS G12 mutations present in 92% of the 500-patient phase 3 study population. In that open-label, multinational trial, patients receiving Rasonque achieved a median overall survival of 12.4 months versus 6.7 months on chemotherapy, with median progression-free survival of 7.2 months compared with 3.6 months. The safety profile included diarrhoea, rash, stomatitis, nausea, and vomiting as the most frequently reported adverse events, a consideration for post-authorisation pharmacovigilance planning across Member States.

The CHMP opinion now moves to the European Commission for a fast-tracked marketing authorisation decision. Pricing and reimbursement negotiations will follow at Member State level, meaning market access timelines will vary by national health system. EMA has indicated it will evaluate further pipeline candidates for phased review on a case-by-case basis, contingent on unmet need and public health significance.

Regulatory affairs teams preparing submissions for oncology assets with breakthrough potential should note that eligibility for phased review remains discretionary, assessed individually against public health criteria rather than applied categorically.

Source: European Medicines Agency (EMA) via ema.europa.eu, 15 October 2026.